214 related articles for article (PubMed ID: 37539777)
21. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
22. A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer.
Wang F; Fan M; Zhou X; Yu Y; Cai Y; Wu H; Zhang Y; Liu J; Huang S; He N; Hu Z; Ding G; Jin X
J Exp Clin Cancer Res; 2021 Jan; 40(1):44. PubMed ID: 33499877
[TBL] [Abstract][Full Text] [Related]
23. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of miR-125b promotes resistance of glioma cells to TRAIL through overexpression of Tafazzin which is a mitochondrial protein.
Ma W; Cui Y; Liu M; Tan Z; Jiang Y
Aging (Albany NY); 2019 May; 11(9):2670-2680. PubMed ID: 31056533
[TBL] [Abstract][Full Text] [Related]
25. Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.
Gupta N; Kumar R; Seth T; Garg B; Sharma A
RNA Biol; 2020 Jan; 17(1):98-111. PubMed ID: 31532704
[TBL] [Abstract][Full Text] [Related]
26. PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7/NF-κB pathway in multiple myeloma.
Shen X; Kong S; Yang Q; Yin Q; Cong H; Wang X; Ju S
J Cell Mol Med; 2020 Mar; 24(6):3492-3503. PubMed ID: 32048803
[TBL] [Abstract][Full Text] [Related]
27. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
[TBL] [Abstract][Full Text] [Related]
28. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
29. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
30. DCAF1-targeting microRNA-3175 activates Nrf2 signaling and inhibits dexamethasone-induced oxidative injury in human osteoblasts.
Chen J; Liang JQ; Zhen YF; Chang L; Zhou ZT; Shen XJ
Cell Death Dis; 2021 Oct; 12(11):1024. PubMed ID: 34716304
[TBL] [Abstract][Full Text] [Related]
31. Effect of miR-101 on proliferation and oxidative stress-induced apoptosis of breast cancer cells via Nrf2 signaling pathway.
Yi J; Huang WZ; Wen YQ; Yi YC
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8931-8939. PubMed ID: 31696480
[TBL] [Abstract][Full Text] [Related]
32. miR-214 protects erythroid cells against oxidative stress by targeting ATF4 and EZH2.
Gao M; Liu Y; Chen Y; Yin C; Chen JJ; Liu S
Free Radic Biol Med; 2016 Mar; 92():39-49. PubMed ID: 26791102
[TBL] [Abstract][Full Text] [Related]
33. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.
Chaulk SG; Lattanzi VJ; Hiemer SE; Fahlman RP; Varelas X
J Biol Chem; 2014 Jan; 289(4):1886-91. PubMed ID: 24324261
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
35. TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
Yang L; Wang B; Jiao X; Zhou C; Chen S; Gao X; Sun W; Song S; Li J; Liu J; Wang Y; Liu P
Breast Cancer Res; 2021 Sep; 23(1):89. PubMed ID: 34488828
[TBL] [Abstract][Full Text] [Related]
36. [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting
Zhang Y; Chen TT; Zhou HB; Chen WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):801-809. PubMed ID: 37356943
[TBL] [Abstract][Full Text] [Related]
37. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-140-5p attenuated oxidative stress in Cisplatin induced acute kidney injury by activating Nrf2/ARE pathway through a Keap1-independent mechanism.
Liao W; Fu Z; Zou Y; Wen D; Ma H; Zhou F; Chen Y; Zhang M; Zhang W
Exp Cell Res; 2017 Nov; 360(2):292-302. PubMed ID: 28928081
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.
Li Z; Wong KY; Calin GA; Chng WJ; Chan GC; Chim CS
Clin Epigenetics; 2019 May; 11(1):71. PubMed ID: 31064412
[TBL] [Abstract][Full Text] [Related]
40. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.
Liu P; Zhang H; Liang X; Ma H; Luan F; Wang B; Bai F; Gao L; Ma C
Oncotarget; 2015 Oct; 6(30):29048-59. PubMed ID: 26315112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
